About this ingredient
Ruxolitinib is a prescription medicine classified as a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1 and JAK2 signaling pathways involved in immune and blood-cell regulation. Ruxolitinib is used for specific medical conditions, including certain myeloproliferative disorders and graft-versus-host disease, depending on the formulation and regulatory approval. It is also available as a topical formulation for certain skin conditions in some markets. Ruxolitinib can have significant effects on the immune system and blood counts and should be used only under appropriate medical supervision.
